To provide an income greater than that of the FTSE All Share Index together with capital growth over the longer term.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 6.0% |
AstraZeneca | 4.4% |
BP | 4.3% |
Vodafone | 4.3% |
Royal Dutch Shell | 4.2% |
Imperial Tobacco | 4.0% |
Indus Gas | 3.8% |
Compass Group | 3.4% |
Reed Elsevier | 3.4% |
KSK Power Ventur | 3.4% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 6.0% |
AstraZeneca | 4.4% |
BP | 4.3% |
Vodafone | 4.3% |
Other | 81% |
Date | 18-Jun-2015 |
---|---|
NAV | 108.60p |
Currency | GBP |
Change | -0.070p |
% | -0.06% |
YTD change | 108.60p |
YTD % | n/a |
Fund Inception | 01/01/1963 |
---|---|
Fund Manager | n/a |
TER | 0.88 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research